Every story in this section, newest first — page 239 of 373.
Xtant Medical Holdings (NYSE:XTNT) reported robust financial results for the full year 2025 on Tuesday, marked by double-digit revenue growth and a strategic pivot toward its core orthobiologics business.
TD SYNNEX (NYSE:SNX) reported exceptional financial results for the fiscal first quarter ended February 28, 2026, significantly outperforming its previous guidance across all major metrics.
J.Jill (NYSE:JILL) announced financial results for the fourth quarter and fiscal year ended January 31, 2026, on Tuesday, reporting a 3.1% decrease in quarterly net sales to $138.4 million.
McCormick & Company (NYSE:MKC) announced robust first-quarter fiscal 2026 results on Tuesday, characterized by a significant double-digit increase in net sales following the successful integration of its major regional acquisition.
TOYO (NASDAQ:TOYO) reported a transformative fiscal year 2025 on Tuesday, characterized by a 142% surge in annual revenue as the company successfully scaled its international manufacturing footprint.
Jiayin Group (NASDAQ:JFIN) reported unaudited fourth-quarter and full-year 2025 financial results on Tuesday, detailing a strategic pivot toward asset quality as the Chinese fintech sector undergoes a significant regulatory-driven transition.
LENSAR (NASDAQ:LNSR) reported robust fourth-quarter and full-year 2025 financial results on Tuesday, highlighted by the continued commercial momentum of its ALLY Adaptive Cataract Treatment System.
iHuman (NYSE:IH) reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, revealing a cooling in top-line growth even as the company remains profitable and committed to shareholder returns.
Super Hi (NASDAQ:HDL) reported unaudited full-year 2025 financial results on Tuesday, characterized by a nearly 70% surge in annual profit and double-digit revenue growth in the final quarter.
Sound Group (NASDAQ:SOGP) reported a significant financial turnaround for the fiscal year ended December 31, 2025, characterized by robust revenue growth and a return to bottom-line profitability.
T1 Energy (NYSE:TE) reported record operational performance for the fourth quarter and full-year 2025, driven by a surge in manufacturing throughput and the successful execution of several strategic capital initiatives.
Miniso Group (NYSE:MNSO) reported record-breaking financial results for both the December quarter and the full fiscal year 2025, underpinned by aggressive global brand momentum and a successful fleet-wide store upgrade program.
AleAnna (NASDAQ:ANNA) reported full-year 2025 financial results on Tuesday, swinging to a net income of $2.9 million as the company’s flagship Italian assets reached operational maturity.
Oculis (NASDAQ:OCS) announced on March 31, 2026, that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation to Privosegtor for the treatment of optic neuritis.
Nebius (NASDAQ:NBIS), the AI cloud infrastructure specialist, announced today the construction of a new "AI factory" in Lappeenranta, Finland, with a total capacity of up to 310 MW.
Organigram Global (NASDAQ:OGI) announced today that its shareholders have granted overwhelming approval for the acquisition of Germany’s Sanity Group.
Scienture (NASDAQ:SCNX), a specialty pharmaceutical company focused on developing and commercializing innovative therapies for underserved patient populations, today reported its financial results for the full year ended December 31, 2025.
Reviva Pharmaceuticals Holdings (NASDAQ:RVPH), a clinical-stage pharmaceutical company developing next-generation therapies for central nervous system (CNS) disorders, today announced its financial results and corporate updates for the full year ended December 31, 2025.
Sigma Lithium (NASDAQ:SGML), a global producer of high-purity "Green Lithium" concentrate, today announced its financial and operational results for the fourth quarter of 2025 and the beginning of 2026.
CBAK Energy Technology (NASDAQ:CBAT), a global manufacturer of lithium-ion rechargeable batteries, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Unicycive Therapeutics (NASDAQ:UNCY), a clinical-stage biopharmaceutical company focused on kidney disease therapies, reported its full-year 2025 financial results and provided a business update on March 30, 2026.
Pulsenmore (NASDAQ:PLSM) reported a transformative fiscal year 2025, marked by a 374% increase in annual revenue and critical regulatory clearances that position the company for a high-growth trajectory in the remote-care sector.
Kenon Holdings (NYSE:KEN), a holding company with interests in energy and shipping, reported its consolidated financial results for the full year 2025, driven largely by performance at its OPC Energy subsidiary.
XBP Global (NASDAQ:XBP) characterized 2025 as a transformative "transition year," reporting full-year results that reflect the significant structural impact of its July 2025 acquisition of BPA.
